ERBB2 and cancer: ErbB2 and ErbB3 interact with EGFR in cancer cells25; MET receptors, CD44, EPHA2, and PDGFRb are implicated in resistance to EGFR-targeted drugs by circumventing the signaling pathway that the drug targets26–29.